No CrossRef data available.
Article contents
TAU Mutations are not a Predominant Cause of Frontotemporal Dementia in Canadian Patients
Published online by Cambridge University Press: 02 December 2014
Abstract
Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective:
Frontotemporal dementia is a neurodegenerative disease affecting mostly the frontal and/or temporal lobes, with neuronal loss and intraneuronal and/or intraglial inclusions composed of hyperphosphorylated microtubule-associated protein tau and ubiquitin. Missense and splice site mutations in the TAU gene have been identified in approximately 15% of all frontotemporal dementia cases. In this study, we evaluated the involvement of mutations in the TAU gene in development of frontotemporal dementia phenotype in patients of French or English Canadian origins.
Methods:
Fourteen patients with frontotemporal dementia phenotype and 98 normal controls were recruited for the study. The TAU gene was screened by sequencing and denaturing high performance liquid chromatography.
Results:
No mutations, except some new polymorphisms, were detected in the TAU gene of these patients. One polymorphism, however, may play a role in pathogenesis.
Conclusion:
Our results agree with previous work suggesting that mutations in this gene are not a frequent cause of the frontotemporal dementia phenotype in Canadian patients.
- Type
- Research Article
- Information
- Copyright
- Copyright © The Canadian Journal of Neurological 2004
References
1.Goedert, M.The significance of tau and a-synuclein inclusions in neurodegenerative diseases. Curr Opin Genet Dev 2001; 11: 343–351.Google Scholar
2.Rosso, SM, Kamphorst, W, de Graaf, B, et al.Familial frontotemporal dementia with ubiquitin-positive inclusions is linked to chromosome 17q21-22. Brain 2001; 124: 1948–1957.Google Scholar
3.Hong, M, Zhukareva, V, Vogelsberg-Ragaglia, V, et al.Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 1998; 282: 1914–1917.Google Scholar
4.Baker, M, Litvan, I, Houlden, H, et al.Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Molec Genet 1999; 8: 711–715.Google Scholar
5.Ingelson, M, Fabre, SF, Lilius, L, et al.Increased risk for frontotemporal dementia through interaction between tau polymorphisms and apolipoprotein E e4. NeuroReport 2001; 12: 905–909.Google Scholar
6.Houlden, H, Baker, M, Morris, HR, et al.Corticobasal degeneration and progressive supranuclear palsy share a common haplotype. Neurology 2001; 56: 1702–1706.Google Scholar
7.Poorkaj, P, D’Souza, I, Bird, TD, Schellenberg, GD.Tau mutations: genetics and pathogenetic mechanisms. In: Lee, VM-Y, Trojanowski, JQ, Buee, L, Christen, Y, (Eds). Fatal Attractions: Protein Aggregates in Neurodegenerative Disorders. Berlin, Germany: Springer-Verlag Heidelberg, 2000: 53–64.Google Scholar
8.Varani, L, Hasegawa, M, Spillantini, MG, et al.Structure of tau exon 10 slicing regulatory element RNA and destabilization by mutations of frontotemeporal dementia and parkinsonism linked to chromosome 17. Proc Natl Acad Sci USA 1999; 96: 8229–8234.Google Scholar
9.D’Souza, I, Poorkaj, P, Hong, M, et al.Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. Proc Natl Acad Sci USA 1999; 96: 5598–5603.Google Scholar
10.Hutton, M.Missence and splice site mutations in tau associated with FTDP-17: multiple pathogenic mechanisms. Neurology 2001; 56: S21–S25.Google Scholar
11.Goedert, M, Spillantini, MG.Tauopathies and a-synucleopathies. In: Lee, VM-Y, Trojanowski, JQ, Buee, L, Christen, Y, (Eds). Fatal Attractions: Protein Aggregates in Neurodegenerative Disorders. Berlin, Germany: Springer-Verlag Heidelberg, 2000: 65–75.Google Scholar
12.Von Bergen, M, Barghorn, S, Li, L, et al.Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local b-structure. J Biol Chem 2001; 276: 48165–48174.CrossRefGoogle Scholar
13.Drewes, G, Ebneth, A, Preuss, U, Mandelkow, EM, Mandelkow, E.MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption. Cell 1997; 89: 297–308.Google Scholar
14.Iwatsubo, T, Hasegawa, M, Ihara, Y.Neuronal and glial tau-positive inclusions in diverse neurologic diseases share common phosphorylation characteristics. Acta Neuropathol 1994; 88: 129–136.CrossRefGoogle ScholarPubMed
15.Hosler, BA, Siddique, T, Sapp, PC, et al.Linkage of familial Amyotrophic Lateral Sclerosis with Frontotemporal Dementia to chromosome 9q21-22. JAMA 2000; 284: 1664–1669.CrossRefGoogle Scholar
16.Garcia, ML, Cleveland, DW.Going new places using an old MAP: tau, microtubules and human neurodegenerative disease. Curr Opin Cell Biol 2001; 13: 41–48.Google Scholar
17.Brun, A, Englund, B, Gustafson, L, et al.(The Lund and Manchester Groups) Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry 1994; 57:416–418.Google Scholar
18.Rizzu, P, van Swieten, JC, Joosse, M, et al.High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands. Am J Hum Genet 1999; 64: 414–421.CrossRefGoogle Scholar
19.Morris, HR, Khan, MN, Janssen, JC, et al.The genetic and pathological classification of familial frontotemporal dementia. Arch Neurol 2001; 58: 1813–1816.Google Scholar
You have
Access